WIN 63843: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 1684 |
| CHEMBL ID | 29609 |
| SCHEMBL ID | 49383 |
| MeSH ID | M0296763 |
| Synonym |
|---|
| win-63843 |
| sr-263843 |
| vp-63843 |
| picovir |
| sr-63843 |
| D05528 |
| pleconaril (usan/inn) |
| 153168-05-9 |
| W11 , |
| 3-{3,5-dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-5-trifluoromethyl-[1,2,4]oxadiazole |
| 3-[3,5-dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |
| pleconaril |
| 1,3-dimethyl-2-[3-(3-methylisoxazol-5-yl)propoxy]-5-[5-(trifluoromethyl)(1,2,4-oxadiazol-3-yl)]benzene |
| vp63843 |
| win63843 |
| 1,2,4-oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- |
| pleconaril [usan:inn] |
| 3-(4-(3-(3-methyl-5-isoxazolyl)propoxy)-3,5-xylyl)-5-trifluoromethyl)-1,2,4-oxadizole |
| vp 63843 |
| win 63843 |
| 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole |
| 3-(3,5-dimethyl-4((3-(3-methyl-5-isoxazolyl)propyl)phenyl)-5-trifluoromethyl)-1,2,4-oxadiazole |
| CHEMBL29609 , |
| bdbm50111469 |
| 5-[3-[2,6-dimethyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]propyl]-3-methylisoxazole |
| 3-(3,5-dimethyl-4-(3-(3-methylisoxazol-5-yl)propoxy)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole |
| pleconaril3-{3,5-dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-5-trifluoromethyl-[1,2,4]oxadiazole |
| 3-{3,5-dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-5-trifluoromethyl-[1,2,4]oxadiazole(pleconaril) |
| pleconaril-d8 |
| 3-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |
| AKOS016005860 |
| FT-0673965 |
| FT-0673964 |
| 9h4570q89d , |
| unii-9h4570q89d |
| 3-[3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |
| pleconaril [mi] |
| pleconaril [mart.] |
| pleconaril [who-dd] |
| pleconaril [usan] |
| pleconaril [inn] |
| DB05105 |
| SCHEMBL49383 |
| tox21_113756 |
| dtxsid8057649 , |
| dtxcid9031438 |
| NCGC00253627-01 |
| cas-153168-05-9 |
| HY-19952 |
| CS-5475 |
| sr-01000945059 |
| SR-01000945059-1 |
| pleconaril, >=98% (hplc) |
| 3-[3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole; picovir; pleconaril; vp 63843; win 63843 |
| J-008988 |
| pleconarilis |
| 3-{3,5-dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl}-5-(trifluoromethyl)-1,2,4-oxadiazole |
| BCP20819 |
| F20826 |
| pleconaril;vp 63843;win 63843 |
| EX-A1448 |
| 3-(3,5-dimethyl-4-(3-(3-methyl-1,2-oxazol-5-yl)propoxy)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole |
| Q770293 |
| mfcd00923611 |
| A847822 |
| AC-36849 |
| pleconaril 100 microg/ml in acetonitrile |
| AS-77268 |
| kqoxlkojhvftrn-uhfffaoysa-n |
| 3-(3,5-dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole |
Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat Picornaviridae infections. The drug is in its late clinical trials stage. Pleconarill is a broad-spectrum antirhinovirus and antienterovirus compound.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pleconaril is a capsid inhibitor used previously to treat enterovirus infections. " | ( Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. Benschop, KSM; Koen, G; Minnaar, RP; Pajkrt, D; van den Broek, PJ; van Hemert, FJ; Vossen, ACTM; Westerhuis, BM; Wildenbeest, JG; Wolthers, KC, 2015) | 2.08 |
| "Pleconaril is an antiviral agent with in vitro activity against HEVs that has been used in the treatment of HEV infections." | ( Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. Benschop, KS; Koen, G; Kuijpers, TW; van den Broek, PJ; Vossen, AC; Wierenga, PC; Wildenbeest, JG; Wolthers, KC, 2012) | 2.54 |
| "Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat Picornaviridae infections, and is in its late clinical trials stage." | ( In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain. Hussain Basha, S; Prasad, RN, 2012) | 1.41 |
| "Pleconaril is a novel, orally available, systemically acting molecule whose pharmacokinetics are characterized by a two-compartment open model with first-order absorption and with a safety profile similar to that of placebo." | ( Pleconaril, a novel antipicornaviral agent. Florea, NR; Maglio, D; Nicolau, DP, 2003) | 2.48 |
| "Pleconaril is a new orally acting antiviral drug with broad anti-picornavirus activity, which provides to treat rhinoviral and enteroviral infections." | ( [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril]. Burtzlaff, C; Friedrich, B; Lauffer, H; Utzig, N, ) | 1.08 |
| "Pleconaril is an investigational agent that inhibits viral attachment to host cell receptors and uncoating of viral nucleic acid." | ( Presentation, diagnosis, and management of enterovirus infections in neonates. Abzug, MJ, 2004) | 1.04 |
| "Pleconaril is a broad-spectrum antirhinovirus and antienterovirus compound that binds into a hydrophobic pocket within viral protein 1, stabilizing the capsid and resulting in the inhibition of cell attachment and RNA uncoating. " | ( Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. Bator, CM; Chakravarty, S; Demenczuk, TM; Ledford, RM; Pevear, DC; Rossmann, MG; Simpson, AA; Skochko, GA; Watanyar, A; Zhang, Y, 2004) | 1.77 |
| "Pleconaril is a novel capsid inhibitor of HRVs." | ( Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Collett, MS; Ledford, RM; Pevear, DC, 2005) | 1.27 |
| "Pleconaril is a viral capsid inhibitor under evaluation for treatment of infections caused by rhinoviruses and enteroviruses. " | ( The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. Bertino, JS; Gartung, AM; Liu, S; Ma, JD; Nafziger, AN; Rhodes, G, 2006) | 2.1 |
| "Pleconaril is an orally active broad-spectrum antipicornaviral agent which demonstrates excellent penetration into the central nervous system, liver, and nasal epithelium. " | ( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food. Abdel-Rahman, SM; Kearns, GL, 1998) | 2.02 |
| "Pleconaril is an orally active, broad-spectrum antipicornaviral agent which demonstrates excellent penetration into the central nervous system, liver, and nasal epithelium. " | ( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network. Abdel-Rahman, SM; Blowey, DL; Jacobs, RF; James, LP; Kearns, GL; Marshall, JD; Wells, TG, 1999) | 2.03 |
| "Pleconaril (VP 63843) is a novel orally bioavailable small molecule with broad antipicornavirus (enterovirus and rhinovirus) activity. " | ( Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. Groarke, JM; Pevear, DC, 1999) | 2.05 |
| "Pleconaril is an orally active broad-spectrum antipicornaviral agent with excellent penetration into the central nervous system and nasal epithelium. " | ( Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. Abdel-Rahman, SM; Kearns, GL, 1999) | 2 |
| "Pleconaril is an orally active, broad spectrum antipicornaviral agent with activity against nonpolio enteroviruses. " | ( Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Abdel-Rahman, SM; Bradley, JS; Capparelli, EV; Jacobs, RF; James, LP; Johnson, KM; Kearns, GL, 2000) | 2.03 |
| "Pleconaril is a novel compound that integrates into the capsid of picornaviruses, including enteroviruses and rhinoviruses, preventing the virus from attaching to cellular receptors and uncoating to release RNA into the cell." | ( Treatment of potentially life-threatening enterovirus infections with pleconaril. Rotbart, HA; Webster, AD, 2001) | 1.27 |
| "Pleconaril appears to be a promising drug for the treatment of enteroviral and rhinoviral infections." | ( Pleconaril: a novel antipicornaviral drug. Romero, JR, 2001) | 2.47 |
| "Pleconaril is an oral antiviral agent being developed by ViroPharma and Sanofi-Synthélabo (formerly Sterling Winthrop) for the potential treatment of several picornavirus-induced infections, including respiratory diseases and viral meningitis. " | ( Pleconaril Sanofi Synthélabo/ViroPharma. Billich, A, 2000) | 3.19 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pleconaril has demonstrated an excellent safety profile in dose escalation and clinical studies." | ( Pleconaril: a novel antipicornaviral drug. Romero, JR, 2001) | 2.47 |
Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials. Treatment increased the survival rate in all three models for both prophylactic and therapeutic dosing regimens.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Plasma concentration-versus-time data were curve fitted for each subject by using a nonlinear weighted least-squares algorithm, and pharmacokinetic parameters were determined from the polyexponential estimates." | ( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food. Abdel-Rahman, SM; Kearns, GL, 1998) | 0.58 |
| " Plasma drug concentration-time data for each subject were fitted to the curve by using a nonlinear, weighted (weight = 1/Ycalc) least-squares algorithm, and model-dependent pharmacokinetic parameters were determined from the polyexponential parameter estimates." | ( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network. Abdel-Rahman, SM; Blowey, DL; Jacobs, RF; James, LP; Kearns, GL; Marshall, JD; Wells, TG, 1999) | 0.58 |
| " A significant difference in both Cmax and AUC was observed between study groups; however, this difference became insignificant when the parameters were corrected for dose." | ( Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. Abdel-Rahman, SM; Kearns, GL, 1999) | 0.56 |
| " Pharmacokinetic parameter estimates were determined by noncompartmental methods and compared between doses and with similar data obtained from a previous study of pleconaril disposition in children (n = 18, 2 to 12 years)." | ( Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Abdel-Rahman, SM; Bradley, JS; Capparelli, EV; Jacobs, RF; James, LP; Johnson, KM; Kearns, GL, 2000) | 0.79 |
Pleconaril is orally bioavailable and achieves serum concentrations in excess of those required to inhibit 90% of clinical rhino- and enteroviral isolates in vitro. The apparent age-dependent differences in the pharmacokinetics of ple Conaril may in part be related to increased bioavailability of the drug in older children and adults.
| Excerpt | Reference | Relevance |
|---|---|---|
| " The apparent bioavailability of pleconaril oral solution was significantly increased with the administration of food." | ( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food. Abdel-Rahman, SM; Kearns, GL, 1998) | 0.86 |
| "Pleconaril (VP 63843) is a novel orally bioavailable small molecule with broad antipicornavirus (enterovirus and rhinovirus) activity." | ( Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. Groarke, JM; Pevear, DC, 1999) | 2.05 |
| "The apparent age-dependent differences in the pharmacokinetics of pleconaril may in part be related to increased bioavailability of the drug in older children and adults than in neonates." | ( Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Abdel-Rahman, SM; Bradley, JS; Capparelli, EV; Jacobs, RF; James, LP; Johnson, KM; Kearns, GL, 2000) | 0.83 |
| " Pleconaril is orally bioavailable and achieves serum concentrations in excess of those required to inhibit 90% of clinical rhino- and enteroviral isolates in vitro." | ( Pleconaril: a novel antipicornaviral drug. Romero, JR, 2001) | 2.66 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 23.8675 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 20.4591 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 26.6032 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 38.9018 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 23.7101 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 28.7673 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.1317 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| G | Vesicular stomatitis virus | Potency | 19.4971 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 21.8761 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 6.6819 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 14.1855 | 0.0016 | 28.0151 | 77.1139 | AID1259385; AID1259395 |
| Interferon beta | Homo sapiens (human) | Potency | 19.4971 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 19.4971 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 19.4971 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 19.4971 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 (µMol) | 30.0593 | 0.0001 | 1.7740 | 10.0000 | AID622597; AID622602 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 28.2141 | 0.0001 | 1.7536 | 10.0000 | AID622601; AID622606 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 25.6888 | 0.0000 | 2.0151 | 10.0000 | AID622600; AID622605 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 30.0593 | 0.0000 | 2.8005 | 10.0000 | AID622598; AID622603 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 30.0593 | 0.0000 | 2.3983 | 10.0000 | AID622599; AID622604 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | EC50 (µMol) | 0.2512 | 0.0020 | 3.5196 | 10.0000 | AID622607 |
| Genome polyprotein | Human rhinovirus sp. | EC50 (µMol) | 0.0580 | 0.0050 | 0.0932 | 0.4400 | AID161553 |
| Genome polyprotein | Human rhinovirus 1A | EC50 (µMol) | 16.0915 | 0.0040 | 0.1046 | 0.4900 | AID1386531; AID1386534; AID1386535; AID1386536; AID1386537; AID1386538; AID1386539; AID1386540 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1427855 | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs | |||
| AID84577 | Anti-HRV activity against HRV serotype 86 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID84570 | Anti-HRV activity against HRV serotype 45 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1890694 | Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID760198 | Antienteroviral activity against Human rhinovirus 39 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1890711 | Antiviral activity against Human rhinovirus B14 infected in human H1-HeLa cells assessed as reduction in viral replication by measuring viral production measured 3 days post infection by crystal violet staining based plaque reduction assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID84564 | Anti-HRV activity against HRV serotype 14 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1352178 | Antiviral activity against Coxsackievirus B5 Ohio-1 ATCC VR 29 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Quinoxaline derivatives as new inhibitors of coxsackievirus B5. |
| AID1380017 | Cytotoxicity in un-infected human HeLa Rh cells assessed as reduction in cell viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study. |
| AID674368 | Antiviral activity against Coxsackievirus B3 assessed as inhibition of viral replication | 2012 | Journal of natural products, Jun-22, Volume: 75, Issue:6 | Alkaloids from the root of Isatis indigotica. |
| AID1445128 | Resistance index, ratio of EC50 for Human rhinovirus B14 harboring VP1 C199Y mutant infected in human HeLa Rh cells to EC50 for Human rhinovirus B14 infected in human H1HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID673872 | Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID161553 | Inhibition of HRV Protease 3CP (serotype 14). | 2002 | Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8 | Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. |
| AID1503325 | Antiviral activity against Human enterovirus B Faulkner ATCC VR 185 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1386533 | Selectivity index, ratio of CC50 for human HeLa Rh cells to EC50 for Rhinovirus B14 capsid infected in human HeLa Rh cells | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1386544 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 4 times EC50 concentration after 1st passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID622604 | Time dependent inhibition of CYP2C19 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1454151 | Antiviral activity against human rhinovirus 71 infected in human H1HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID161529 | cytotoxicity against HRV Protease 3CP (serotype 14) | 2002 | Journal of medicinal chemistry, Apr-11, Volume: 45, Issue:8 | Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. |
| AID1384981 | Antiviral activity against Human rhinovirus A71 infected in human H1HeLa cells assessed as inhibition of viral replication after 3 days by MTT assay | 2018 | ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7 | 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus. |
| AID1386534 | Inhibition of Rhinovirus A02 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID246109 | Effective concentration against HRV serotype 86 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1384979 | Antiviral activity against Human rhinovirus B14 infected in human H1HeLa cells assessed as inhibition of viral replication after 3 days by MTT assay | 2018 | ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7 | 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus. |
| AID1917974 | Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus-D68 STL-2014-12 infected in human RD cells to | |||
| AID316860 | Inhibition of HRV2 replication cycle progression | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1386552 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at EC50 concentration after 3rd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1386537 | Inhibition of Rhinovirus A85 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID84567 | Anti-HRV activity against HRV serotype 2 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID84571 | Anti-HRV activity against HRV serotype 51 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID84578 | Anti-HRV activity against HRV serotype 89 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1386543 | Antiviral activity against Rhinovirus B14 infected in human HeLa Rh cells assessed as reduction in viral replication at 1 uM administered at >= 2 hrs post infection measured after 8 hrs post infection by RT-qPCR analysis | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID760194 | Antienteroviral activity against Human rhinovirus 59 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID246106 | Effective concentration against HRV serotype 70 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID760199 | Antienteroviral activity against Human rhinovirus 29 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1261313 | Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1445119 | Antiviral activity against Human rhinovirus B14 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated 1 hr prior to infection by DAPI staining based immunofluorescence assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1736126 | Antiviral activity against pleconaril-resistant Coxsackievirus B3 97927 11207T/I1092 mutant infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID622589 | Antiviral activity against Human rhinovirus 2 infected in human HeLa Ohio cells assessed as inhibition of virus-induced cytopathic effect by CellTiter-Glo assay | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1386541 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as reduction in viral replication at 1 uM administered 2 hrs before infection measured after 8 hrs post infection by RT-qPCR analysis | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1736143 | Induction of CYP3A4 (unknown origin) in hepatocytes using midazolam as substrate at 10 uM relative to control | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID316852 | Antiviral activity against HRV14 in HeLa cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID760208 | Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID84574 | Anti-HRV activity against HRV serotype 70 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1454150 | Antiviral activity against human rhinovirus 21 infected in human H1HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID622592 | Unbound fraction in rat plasma | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1503725 | Antiviral activity against Human rhinovirus serotype 14 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 24 to 36 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders. |
| AID1654872 | Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID622676 | Activation of human PXR expressed in african green monkey CV1 cells transfected with pSG5-hPXRDATG and (ER6)3-tk-CAT reporter assessed as maximal activation relative to control | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1386549 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at EC50 concentration after 2nd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1503324 | Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1380016 | Antiviral activity against Human rhinovirus B14 infected in human HeLa Rh cells assessed as protection against virus induced cytopathic effect after 3 days in presence of 10% inactivated FBS by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study. |
| AID316861 | Inhibition of HRV16 replication cycle progression | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1445115 | Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1917977 | Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus-D68 US/KY/14-18953 infected in human RD cells | |||
| AID1261312 | Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1917979 | Antiviral activity against Enterovirus-D68 US/MO/14-18947 infected in human RD cells assessed as reduction in virus induced cytopathic effect by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay | |||
| AID1386536 | Inhibition of Rhinovirus A28 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1890701 | Antiviral activity against Rhinovirus A33 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID568502 | Antiviral activity against HRV-14 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors. |
| AID1386548 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 2 times EC50 concentration after 2nd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1454149 | Antiviral activity against human rhinovirus 14 infected in human H1HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID622602 | Time dependent inhibition of CYP1A2 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1503327 | Antiviral activity against Enterovirus C Sabin ATCC VR 534 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 2 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID246104 | Effective concentration against HRV serotype 59 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID622603 | Time dependent inhibition of CYP2C9 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1386546 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at EC50 concentration after 1st passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID673876 | Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1890691 | Antiviral activity against Human rhinovirus B14 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1917980 | Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus-D68 US/MO/14-18947 infected in human RD cells | |||
| AID673877 | Ratio of EC50 for Human rhinovirus B to EC50 for Human rhinovirus A | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1386554 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 2 times EC50 concentration after 4th passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID760190 | Antienteroviral activity against Human rhinovirus 85 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1445129 | Cytotoxicity against human HeLa Rh cells assessed as decrease in cell viability after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID622596 | Apparent permeability of compound by PAMPA | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1890693 | Antiviral activity against Human rhinovirus A71 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1386540 | Inhibition of Rhinovirus B70 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1890699 | Antiviral activity against Human rhinovirus 2 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1890692 | Antiviral activity against Human rhinovirus A21 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID760185 | Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1736124 | Antiviral activity against pleconaril-resistant Coxsackievirus B3 97927 11207K/I1092 mutant infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID84565 | Anti-HRV activity against HRV serotype 15 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID760189 | Antienteroviral activity against Human rhinovirus 86 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1386539 | Inhibition of Rhinovirus B42 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID622588 | Antiviral activity against Human rhinovirus 14 infected in human HeLa Ohio cells assessed as inhibition of virus-induced cytopathic effect by CellTiter-Glo assay | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1445127 | Resistance index, ratio of EC50 for Human rhinovirus B14 harboring VP1 A150V/E276K double mutant infected in human HeLa Rh cells to EC50 for Human rhinovirus B14 infected in human H1HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID760206 | Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID246084 | Effective concentration against HRV serotype 9 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1917970 | Antiviral activity against Enterovirus-D68 infected in human HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 4 hrs by plaque reduction assay | |||
| AID297238 | Selectivity index, ratio of CC50 for HeLa cells to IC50 for HRV2 | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. |
| AID1890695 | Selectivity index, ratio of CC50 for cytotoxicity against human H1-HeLa cells to EC50 for antiviral activity against Human rhinovirus B14 infected in human H1-HeLa cells | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1654869 | Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID760191 | Antienteroviral activity against Human rhinovirus 72 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1386531 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1917973 | Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay | |||
| AID673879 | Ratio of EC50 for major receptor-resistant Human rhinovirus B to EC50 for minor receptor-resistant Human rhinovirus A | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1235016 | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CPE assay | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID1445122 | Antiviral activity against Human rhinovirus A16 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated 1 hr prior to infection by DAPI staining based immunofluorescence assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID622601 | Inhibition of CYP3A4 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID316851 | Antiviral activity against HRV1A in HeLa cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1562985 | Cytotoxicity against human HeLa cells after 3 days by MTT assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
| AID1890698 | Antiviral activity against Rhinovirus A1B infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1890705 | Antiviral activity against Human rhinovirus 86 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1736129 | Antiviral activity against Rhinovirus B14 infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 72 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID1445111 | Antiviral activity against Human rhinovirus A71 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID246083 | Effective concentration against HRV serotype 2 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1917975 | Antiviral activity against Enterovirus-D68 US/KY/14-18953 infected in human RD cells assessed as reduction in virus induced cytopathic effect by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay | |||
| AID760201 | Antienteroviral activity against Human rhinovirus 9 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID622606 | Time dependent inhibition of CYP3A4 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID84572 | Anti-HRV activity against HRV serotype 59 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1736128 | Antiviral activity against Rhinovirus B5 infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 72 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID1736125 | Antiviral activity against pleconaril-resistant Coxsackievirus B3 97927 11207M/I1092 mutant infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID1386550 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 4 times EC50 concentration after 3rd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID84576 | Anti-HRV activity against HRV serotype 85 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1261342 | Antiviral activity against Vaccinia virus | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1454144 | Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID1890702 | Antiviral activity against Rhinovirus A98 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID760187 | Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1352177 | Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Quinoxaline derivatives as new inhibitors of coxsackievirus B5. |
| AID1261324 | Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID760192 | Antienteroviral activity against Human rhinovirus 70 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID673874 | Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID163808 | Inhibitory activity against human rhinovirus-14 3C protease; Not applicable | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. |
| AID316858 | Inhibition of HRV2 absorption on HeLa cells assessed as reduction in plaques at 0.25 ug/ml after 2 hrs | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1261328 | Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1294752 | Antiviral activity against Human Rhinovirus A serotype 2 infected in HeLa Rh cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection. |
| AID246098 | Effective concentration against HRV serotype 15 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1204080 | Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11 | N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. |
| AID1445113 | Selectivity index, ratio of CC50 for human H1HeLa cells to EC50 for Human rhinovirus A21 infected in human H1HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID760200 | Antienteroviral activity against Human rhinovirus 15 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID84566 | Anti-HRV activity against HRV serotype 16 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1445125 | Antiviral activity against Human rhinovirus B14 harboring VP1 A150V/E276K double mutant infected in human HeLa Rh cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID622681 | Lipophilicity, log D of the compound | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID84569 | Anti-HRV activity against HRV serotype 39 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1386551 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 2 times EC50 concentration after 3rd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID622607 | Activation of human PXR expressed in african green monkey CV1 cells transfected with pSG5-hPXRDATG and (ER6)3-tk-CAT reporter | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID246103 | Effective concentration against HRV serotype 51 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1204074 | Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method | 2015 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11 | N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. |
| AID246110 | Effective concentration against HRV serotype 89 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID246060 | Median effective concentration against HRV serotypes; Number of serotypes 16 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1261308 | Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID760195 | Antienteroviral activity against Human rhinovirus 45 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID622594 | Intrinsic clearance in Sprague-Dawley rat hepatocytes assessed per 10'6 cells preincubated for 5 mins measured after 90 mins | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1454146 | Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID316853 | Antiviral activity against HRV16 in HeLa cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1261315 | Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1454145 | Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID1386542 | Antiviral activity against Rhinovirus B14 infected in human HeLa Rh cells assessed as reduction in viral replication at 1 uM administered at the time of infection measured after 8 hrs post infection by RT-qPCR analysis | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1454148 | Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID622599 | Inhibition of CYP2C19 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1654875 | Selectivity index, ratio of CC50 for cytotoxicity in African green monkey Vero cells to EC50 for Antiviral activity against Coxsackievirus B3 infected in Vero cells | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID1890714 | Antiviral activity against Human rhinovirus B14 infected in human H1-HeLa cells assessed as reduction in viral titre at 1 uM pretreated for 1 hr followed by viral infection and measured immediately by time-of-addition assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID622595 | Chemical stability of compound assessed as half life | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1917976 | Antiviral activity against Enterovirus-D68 fermon infected in human RD cells assessed as reduction in virus induced cytopathic effect by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay | |||
| AID1204081 | Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11 | N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. |
| AID622593 | Intrinsic clearance in human microsomes after 45 mins by HPLC method | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1890700 | Antiviral activity against Human rhinovirus 16 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID23851 | t1/2 in monkey liver microsomes | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8 | Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. |
| AID1445112 | Selectivity index, ratio of CC50 for human H1HeLa cells to EC50 for Human rhinovirus B14 infected in human H1HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID316855 | Selectivity index, ratio of CC50 for HeLa cells to IC50 for HRV2 in HeLa cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1235015 | Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID1445110 | Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1427861 | Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 infected in African green monkey Vero cells | |||
| AID1445120 | Antiviral activity against Human rhinovirus B14 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated simultaneously with infection by DAPI staining based immunofluorescence assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID246105 | Effective concentration against HRV serotype 63 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1427860 | Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect | |||
| AID1503326 | Selectivity index, ratio of CC50 for African green monkey Vero 76 cells to EC50 for Human coxsackievirus B5 Faulkner | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1736121 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID1386555 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at EC50 concentration after 4th passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID84573 | Anti-HRV activity against HRV serotype 63 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1261310 | Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID760196 | Antienteroviral activity against Human rhinovirus 42 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1917978 | Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus-D68 fermon infected in human RD cells | |||
| AID1454147 | Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones. |
| AID316856 | Inactivation of HRV2 assessed as reduction in plaque at 0.25 ug/ml after 1 hr | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1386532 | Cytotoxicity against human HeLa Rh cells assessed as reduction in cell viability after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID622587 | Antiviral activity against Human rhinovirus 16 infected in human HeLa Ohio cells assessed as inhibition of virus-induced cytopathic effect by CellTiter-Glo assay | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID246102 | Effective concentration against HRV serotype 45 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID760186 | Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1445117 | Selectivity index, ratio of CC50 for human HeLa cells to EC50 for human poliovirus 3 infected in human HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1386545 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 2 times EC50 concentration after 1st passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID760202 | Antienteroviral activity against Human rhinovirus 2 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1890706 | Antiviral activity against Rhinovirus B91 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1261340 | Antiviral activity against HSV1 | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID84568 | Anti-HRV activity against HRV serotype 29 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1261314 | Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1294749 | Antiviral activity against Human Rhinovirus B serotype 14 infected in HeLa Rh cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection. |
| AID1386547 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 4 times EC50 concentration after 2nd passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID316862 | Selectivity for HRV2 over HRV16 | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1261341 | Antiviral activity against VSV | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1890696 | Selectivity index, ratio of CC50 for cytotoxicity against human H1-HeLa cells to EC50 for antiviral activity against Human rhinovirus A21 infected in human H1-HeLa cells | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1294750 | Cytotoxicity against human HeLa Rh cells assessed as cell viability by light microscopy | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection. |
| AID297237 | Antiviral activity against HRV2 in HeLa cells by CPE assay | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. |
| AID1503724 | Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders. |
| AID622590 | Aqueous equilibrium solubility of the compound by shake-flask technique | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID673878 | Ratio of EC50 for antiviral-resistant Human rhinovirus B to EC50 for antiviral-resistant Human rhinovirus A | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1890704 | Antiviral activity against Human rhinovirus 42 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID316854 | Cytotoxicity against human HeLa cells after 72 hrs | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID84561 | In vitro anti-rhinoviral activity against human rhinovirus serotypes 2,3,9,14,16,25 and 39 | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. |
| AID622591 | Unbound fraction in human plasma | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID246097 | Effective concentration against HRV serotype 14 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1384980 | Antiviral activity against Human rhinovirus A21 infected in human H1HeLa cells assessed as inhibition of viral replication after 3 days by MTT assay | 2018 | ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7 | 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus. |
| AID1736123 | Antiviral activity against wild type Coxsackievirus B3 97927 infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID1445126 | Antiviral activity against Human rhinovirus B14 harboring VP1 C199Y mutant infected in human HeLa Rh cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID84579 | Anti-HRV activity against HRV serotype 9 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1445116 | Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1384978 | Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay | 2018 | ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7 | 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus. |
| AID19547 | Tested for pharmacokinetic parameter in fasted Beagle dogs (Half-life) iv administration. | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8 | Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. |
| AID1261323 | Selectivity index, ratio of CC50 for african green monkey Vero76 cells to EC50 for human Sb-1 | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1736127 | Antiviral activity against Rhinovirus A2 infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 72 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID14911 | Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration. | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8 | Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. |
| AID1445109 | Antiviral activity against Human rhinovirus A21 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID246100 | Effective concentration against HRV serotype 29 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID673875 | Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1503726 | Antiviral activity against Human rhinovirus serotype 39 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 24 to 36 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders. |
| AID760193 | Antienteroviral activity against Human rhinovirus 63 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID246101 | Effective concentration against HRV serotype 39 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID622600 | Inhibition of CYP2D6 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1261311 | Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID760197 | Antienteroviral activity against Human rhinovirus 41 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1562984 | Antiviral activity against Enterovirus clinical isolate | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
| AID1445107 | Antiviral activity against Human rhinovirus B14 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated every 1 hr for 9 hrs after infection by DAPI staining based immunofluorescence assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID622597 | Inhibition of CYP1A2 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID1235017 | Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3-induced cytopathic effect in African green monkey Vero cells | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID1918004 | Antiviral activity against Enterovirus D68 infected in human RD cells assessed as reduction in thermal inactivation of virus at 55 degreeC at 12.5 uM incubated for 72 hrs by TCID50 assay | |||
| AID1736144 | Induction of CYP3A4 (unknown origin) in hepatocytes using midazolam as substrate at 1 uM relative to control | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID760188 | Antienteroviral activity against Human rhinovirus 89 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID84575 | Anti-HRV activity against HRV serotype 72 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
| AID1261309 | Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1056521 | Antiviral activity against Coxsackie virus B3 assessed as inhibition of viral replication | 2013 | Journal of natural products, Dec-27, Volume: 76, Issue:12 | Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica. |
| AID1445114 | Selectivity index, ratio of CC50 for human H1HeLa cells to EC50 for Human rhinovirus A71 infected in human H1HeLa cells | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1261326 | Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID760205 | Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1379348 | Inhibition of Enterovirus 71 Shenzhen/120F1/09 capsid infected in human RD cells assessed as reduction in virus-induced cell death after 72 hrs by CCK-8 assay | 2017 | ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8 | Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD. |
| AID1890697 | Selectivity index, ratio of CC50 for cytotoxicity against human H1-HeLa cells to EC50 for antiviral activity against Human rhinovirus A71 infected in human H1-HeLa cells | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID297239 | Cytotoxicity against human HeLa cells | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. |
| AID1386553 | Inhibition of Rhinovirus B14 capsid infected in human HeLa Rh cells assessed as number of wells with full cytopathic effect at 4 times EC50 concentration after 4th passage measured after 3 days by MTS assay relative to control | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1445123 | Antiviral activity against Human rhinovirus A16 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated simultaneously with infection by DAPI staining based immunofluorescence assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID246107 | Effective concentration against HRV serotype 72 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1445108 | Antiviral activity against Human rhinovirus B14 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID1261317 | Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID673873 | Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1380018 | Selectivity index, ratio of CC50 for un-infected human HeLa Rh cells to EC50 for Human rhinovirus B14 infected in human HeLa Rh cells | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study. |
| AID246108 | Effective concentration against HRV serotype 85 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1386535 | Inhibition of Rhinovirus A08 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID246099 | Effective concentration against HRV serotype 16 (assay was run at least six times) | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. |
| AID1261319 | Selectivity index, ratio of CC50 for BHK-21 cells to EC50 for YFV | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID1917972 | Antiviral activity against Enterovirus-D68 STL-2014-12 infected in human RD cells assessed as reduction in virus induced cytopathic effect by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay | |||
| AID256497 | Cytostatic concentration against WI-38 cells | 2005 | Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20 | Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. |
| AID622605 | Time dependent inhibition of CYP2D6 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| AID316850 | Antiviral activity against HRV2 in HeLa cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. |
| AID1261316 | Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID673871 | Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2012 | ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. |
| AID1445118 | Antiviral activity against Human rhinovirus A16 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. |
| AID15655 | Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration. | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8 | Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. |
| AID760203 | Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. |
| AID1890703 | Antiviral activity against Rhinovirus B27 infected in human H1-HeLa cells assessed as reduction in virus induced cytopathic effect incubated for 3 days by MTT assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode. |
| AID1386538 | Inhibition of Rhinovirus A89 capsid infected in human HeLa Rh cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTS assay | 2018 | Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18 | Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. |
| AID1736122 | Antiviral activity against Coxsackievirus B3 Nancy infected in human HeLa cell line assessed as inhibition of virus-induced cytopathic effect measured after 48 hrs by crystal violet uptake assay | 2020 | European journal of medicinal chemistry, Feb-15, Volume: 188 | Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. |
| AID622598 | Inhibition of CYP2C9 | 2011 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20 | Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (10.29) | 18.2507 |
| 2000's | 51 (37.50) | 29.6817 |
| 2010's | 53 (38.97) | 24.3611 |
| 2020's | 18 (13.24) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 16 (11.43%) | 5.53% |
| Reviews | 21 (15.00%) | 6.00% |
| Case Studies | 10 (7.14%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 93 (66.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates With Enteroviral Sepsis Syndrome [NCT00031512] | Phase 2 | 61 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure [NCT00394914] | Phase 2 | 311 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| The Diabetes Virus Detection and Intervention Trial [NCT04838145] | Phase 2 | 96 participants (Actual) | Interventional | 2018-08-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||